Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2440927
Max Phase: Preclinical
Molecular Formula: C84H113F3N18O18
Molecular Weight: 1605.91
Molecule Type: Unknown
Associated Items:
ID: ALA2440927
Max Phase: Preclinical
Molecular Formula: C84H113F3N18O18
Molecular Weight: 1605.91
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NCCN(CCNC(=O)CCC(=O)NCCOCCOCCNC(=O)/N=C(/N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(O)cc1)CCNC(=O)CCC(=O)NCCOCCOCCNC(=O)/N=C(/N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(O)cc1.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C82H112N18O16.C2HF3O2/c83-37-46-100(47-40-86-69(103)33-35-71(105)88-42-49-113-53-55-115-51-44-92-81(111)98-79(84)90-38-13-23-67(75(107)94-57-59-25-29-65(101)30-26-59)96-77(109)73(61-15-5-1-6-16-61)62-17-7-2-8-18-62)48-41-87-70(104)34-36-72(106)89-43-50-114-54-56-116-52-45-93-82(112)99-80(85)91-39-14-24-68(76(108)95-58-60-27-31-66(102)32-28-60)97-78(110)74(63-19-9-3-10-20-63)64-21-11-4-12-22-64;3-2(4,5)1(6)7/h1-12,15-22,25-32,67-68,73-74,101-102H,13-14,23-24,33-58,83H2,(H,86,103)(H,87,104)(H,88,105)(H,89,106)(H,94,107)(H,95,108)(H,96,109)(H,97,110)(H4,84,90,92,98,111)(H4,85,91,93,99,112);(H,6,7)/t67-,68-;/m1./s1
Standard InChI Key: ZCPWOSPECIMESU-UKLKETJRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1605.91 | Molecular Weight (Monoisotopic): 1604.8504 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Keller M, Kaske M, Holzammer T, Bernhardt G, Buschauer A.. (2013) Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors., 21 (21): [PMID:24074877] [10.1016/j.bmc.2013.08.065] |
Source(1):